NSE: ROSSARI | BSE: 543213

Slowing Down Stock

Download real time

504.50 -0.90 (-0.18%)

26.92% Fall from 52W High

18,028 NSE+BSE Volume

NSE 13 Aug, 2026 10:59 AM (IST)

2,794.6

Market Cap

Above industry Median

Beta 1Year

High Volatility

Rossari Biotech Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ROSSARI, BSE:543213 Rossari Biotech Ltd.

Search Inside the pdf :

Rossari Biotech Ltd.

21 Jul 2026

504.50

-0.18%

Operating Leverage, Portfolio Optimisation & Capacity Unlock Drive the Next Growth Phase

Accumulate: Rossari Biotech Ltd.

Recommendation Target

Deven Choksey

Management has guided for ~15% revenue growth in FY27 despite a stronger Q1 run rate, reflecting caution on geopolitical and input cost uncertainties.

Rossari Biotech Ltd. is trading above its 100 day SMA of 499.1

Rossari Biotech Ltd.

21 Jul 2026

504.50

-0.18%

With capacity utilisation ramping up, focus likely shifts to margins

Buy: Rossari Biotech Ltd.

Target

ICICI Securities Limited

Rossari Biotech (Rossari)’s Q1FY27 EBITDA grew 18.8% YoY; however, the company’s margin profile remains constrained due to limited availability of EO, raw-material volatility, and losses in its institutional and B2C businesses.

Rossari Biotech Ltd. is trading above its 100 day SMA of 499.1

Rossari Biotech Ltd.

30 Apr 2026

504.50

-0.18%

Result Update

Buy: Rossari Biotech Ltd.

Target

Deven Choksey

Rossari Biotech closed FY26 on a strong footing, reporting its highest-ever quarterly revenue and EBITDA in Q4, with consolidated revenue from operations for the full year at INR 2,396.4 crore up 15% YoY, driven primarily by volume.

Rossari Biotech Ltd. has an average target of 583.00 from 2 brokers.

Rossari Biotech Ltd.

29 Apr 2026

504.50

-0.18%

Focus on profitable growth, improved utilisation and sale of non-core assets in FY27

Buy: Rossari Biotech Ltd.

Recommendation Target

ICICI Securities Limited

Rossari’s Q4 EBITDA grew 11.2% YoY, while gross/EBITDA margins shrank QoQ due to inferior mix. Rossari has outlined its focus areas for FY27. Grow profitably by improving sales in the high-margin categories of pharma, aroma and personal care; separately, the company plans to exit its low-margin B2C business.

Rossari Biotech Ltd. is trading below its 30 day SMA of 515.4

Rossari Biotech Ltd.

21 Jan 2026

504.50

-0.18%

HPPC and new capacities to drive earnings growth

Buy: Rossari Biotech Ltd.

Target

Deven Choksey

The near-term headwinds—muted domestic demand, elevated employee costs, and gestation-led pressure from new capacities—are likely to keep earnings growth and return ratios subdued over the next few quarters.

Rossari Biotech Ltd. has an average target of 583.00 from 2 brokers.

Rossari Biotech Ltd.

24 Oct 2025

504.50

-0.18%

HPPC and new capacities to drive earnings growth

Buy: Rossari Biotech Ltd.

Target

Deven Choksey

Rossari Biotech continues to execute well operationally, leveraging R&D intensity and export expansion to offset pricing headwinds.

Rossari Biotech Ltd. has an average target of 583.00 from 2 brokers.

Rossari Biotech Ltd.

25 Jul 2025

504.50

-0.18%

HPPC and new capacities to drive earnings growth

Buy: Rossari Biotech Ltd.

Deven Choksey

Rossari Biotech’s Q1FY26 revenue grew by 11.0% YoY (-6.2% QoQ) to INR 5,437 Mn., in-line with our estimates, the growth was entirely driven by volume expansion of 11.0% YoY.